Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase.
about
Neurotrophic Factors and Their Potential Applications in Tissue Regeneration.Transglutaminase is a therapeutic target for oxidative stress, excitotoxicity and stroke: a new epigenetic kid on the CNS blockHuntington's disease: the past, present, and future search for disease modifiers.Mechanisms of RNA-induced toxicity in CAG repeat disordersBDNF deregulation in Rett syndromeMouse models of polyglutamine diseases in therapeutic approaches: review and data table. Part II.Targeted pharmacological treatment of autism spectrum disorders: fragile X and Rett syndromesRett Syndrome: Reaching for Clinical TrialsNo quiet surrender: molecular guardians in multiple sclerosis brainMolecular chaperone mediated late-stage neuroprotection in the SOD1(G93A) mouse model of amyotrophic lateral sclerosisMolecular chaperone-mediated rescue of mitophagy by a Parkin RING1 domain mutantCell death in the nervous systemCysteamine attenuates the decreases in TrkB protein levels and the anxiety/depression-like behaviors in mice induced by corticosterone treatmentDysregulation of C/EBPalpha by mutant Huntingtin causes the urea cycle deficiency in Huntington's diseaseCysteamine treatment ameliorates alterations in GAD67 expression and spatial memory in heterozygous reeler miceESET/SETDB1 gene expression and histone H3 (K9) trimethylation in Huntington's disease.Tissue transglutaminase contributes to the pathogenesis of preeclampsia and stabilizes placental angiotensin receptor type 1 by ubiquitination-preventing isopeptide modification.Involvement of Transglutaminase-2 in α-MSH-Induced Melanogenesis in SK-MEL-2 Human Melanoma Cells.Cystamine protects from 3-nitropropionic acid lesioning via induction of nf-e2 related factor 2 mediated transcription.Cystamine and intrabody co-treatment confers additional benefits in a fly model of Huntington's disease.Therapeutic approaches to preventing cell death in Huntington diseaseTargets for future clinical trials in Huntington's disease: what's in the pipeline?Cystamine preparations exhibit anticoagulant activityTherapeutic advances in Huntington's Disease.Genetics and treatment options for recurrent acute and chronic pancreatitis.Inhibition of transglutaminase 2 mitigates transcriptional dysregulation in models of Huntington disease.Huntington's Disease and Striatal Signaling.Fear conditioning leads to alteration in specific genes expression in cortical and thalamic neurons that project to the lateral amygdala.Cellular therapy and induced neuronal replacement for Huntington's disease.Knock-down of pantothenate kinase 2 severely affects the development of the nervous and vascular system in zebrafish, providing new insights into PKAN diseaseSuppression of protein aggregation by chaperone modification of high molecular weight complexesTransglutaminase 2 inhibitors and their therapeutic role in disease states.Potential drugs and methods for preventing or delaying the progression of Huntington's disease.Transglutaminase inhibition protects against oxidative stress-induced neuronal death downstream of pathological ERK activation.The corticostriatal pathway in Huntington's disease.Elevated Transglutaminase Activity Triggers Angiotensin Receptor Activating Autoantibody Production and Pathophysiology of Preeclampsia.Brain-derived neurotropic factor/TrkB signaling in the pathogenesis and novel pharmacotherapy of schizophrenia.Altered Function of the DnaJ Family Cochaperone DNJ-17 Modulates Locomotor Circuit Activity in a Caenorhabditis elegans Seizure Model.Substrate Reduction Therapy in Four Patients with Milder CLN1 Mutations and Juvenile-Onset Batten Disease Using Cysteamine Bitartrate.Tissue-type transglutaminase and the effects of cystamine on intracerebral hemorrhage-induced brain edema and neurological deficits.
P2860
Q26776474-29C4F940-07C3-4236-8300-13DF7FD24728Q26824549-748A2A0F-8F07-434C-B7D0-647530F86B59Q26830039-434DDC26-EE4B-468D-94C0-D4DFE5BA5F82Q26860030-03EBD04B-0BBA-41D9-9C13-F56A73B91EF2Q27005901-656E7700-E8CE-4AEC-85EA-BC66397DAEF2Q27005950-1E9139C2-B8BB-4AD2-A366-8CF5B86C1F81Q27023257-D8A7C4E3-085B-4647-9798-9D71288924D5Q27337778-F1B49DE5-FC65-4A95-987A-09EF8C005F49Q28084633-6113BB00-367A-44AD-8176-B2D60F36CC78Q28115951-8D35A0BE-E914-4F5E-9006-450450030C99Q28116653-3AF82807-27FF-4125-A9D1-EE3EF96202A8Q28269343-CAD87BA2-4B8B-48D5-B5D4-ED2F0585D14EQ28477574-E480E606-0D0A-415D-A4CA-CE6CDC8ADB0FQ28505492-B28CA4E9-0005-462D-A1D4-FFEAF1235A42Q30464123-09D28135-7E25-482B-B3AB-3A5B9BA50A6AQ30478632-2ED5CFDF-038E-437D-A4FF-4CC20ABE6275Q33737470-33142524-F36C-43F6-92C0-FCD019EDA663Q33765070-288D2587-EBAA-416F-B3D4-D41930AACA62Q33912442-85D92F76-A864-4BD0-B7F8-1644F297DC04Q34077018-E55D7A38-D8F5-4BDD-A094-106B3BAA6B5AQ34411338-CFBC1BDF-0F4E-4A60-9C0B-06CFFD6C68BEQ34435001-56630997-8893-4561-9C16-5130BF5FF627Q34473794-84BC840F-7FD2-45C8-932D-F3271ABC968DQ34487604-70B7CC8E-6FC1-4C92-AE08-3C9EBB7C95D1Q34581965-48F9EC24-B161-47ED-8CA4-7B1622366DFFQ34743269-7B5503B3-50D9-400C-945C-AB954ABCB0CAQ35286098-76E74A95-3673-4024-953E-CF37E20E6680Q35373330-AD5975C4-2785-4021-B330-CBE722C1CAE7Q35648164-863F94BD-A6B2-4E85-BA1D-63F74B655EDAQ35811397-8C1C43C3-BA6D-440A-A60F-CF9DCA398621Q35888633-55FEFA72-0181-4030-9E29-0B1D1195ACB3Q35989247-B7BD6907-B7A5-4D9D-8FC9-0F911E4DFD96Q36142706-65317596-2F75-4821-87DE-71D8F3A2E2ABQ36241237-69BBDABD-A2AA-478E-90EF-2FDDAA37E8FBQ36684263-50E5BDBC-4C42-4A2C-9CE3-D0C1D1638622Q36836373-AAE1A479-8A31-4F9C-BCAE-0E14CEADAF37Q37078047-EF9D8AEF-CE8C-4E42-A464-588B55F5F588Q37079604-D05447D3-9AF0-4706-A2CB-4F4D107C426BQ37127591-60525D73-5517-4B33-BE03-62F9C4D4DA6DQ37195530-FA594E09-9CDD-433E-A12E-66801824C736
P2860
Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase.
description
2006 nî lūn-bûn
@nan
2006 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Cystamine and cysteamine incre ...... via HSJ1b and transglutaminase
@nl
Cystamine and cysteamine incre ...... ia HSJ1b and transglutaminase.
@ast
Cystamine and cysteamine incre ...... ia HSJ1b and transglutaminase.
@en
type
label
Cystamine and cysteamine incre ...... via HSJ1b and transglutaminase
@nl
Cystamine and cysteamine incre ...... ia HSJ1b and transglutaminase.
@ast
Cystamine and cysteamine incre ...... ia HSJ1b and transglutaminase.
@en
prefLabel
Cystamine and cysteamine incre ...... via HSJ1b and transglutaminase
@nl
Cystamine and cysteamine incre ...... ia HSJ1b and transglutaminase.
@ast
Cystamine and cysteamine incre ...... ia HSJ1b and transglutaminase.
@en
P2093
P2860
P50
P3181
P356
P1476
Cystamine and cysteamine incre ...... ia HSJ1b and transglutaminase.
@en
P2093
Christian Néri
Elzbieta A Bryson
Etienne Hirsch
Frédéric Saudou
Ghislaine Grange
J Alex Parker
Maria Borrell-Pagès
Martine Guillermier
Philippe Hantraye
Sandrine Humbert
P2860
P304
P3181
P356
10.1172/JCI27607
P407
P50
P577
2006-04-06T00:00:00Z